Predictive Technology Group Inc (PREDQ)

Predictive Technology Group Inc. is a common stock listing on OTC Markets for a healthcare-focused biotechnology company. Through its subsidiaries, the company developed and commercialized molecular diagnostic, therapeutic, and human cellular and tissue-based products. Its business was organized into two segments: Human Cellular and Tissues Products (HCT/Ps) and Diagnostics and Therapeutics. The company’s products and services included FertilityDX, a genetic testing service for couples facing infertility, ARTguide, a genetic test used in cases involving endometriosis and other genetic conditions, and regenerative medicine products such as AmnioCyte, AmnioCyte Plus, PolyCyte, and CoreCyte. Predictive Technology Group also maintained a collaboration with Atrin Pharmaceuticals LLC focused on developing molecular diagnostic tools for improved cancer patient selection. Founded in 2005 and headquartered in Salt Lake City, Utah, the company previously operated as Global Enterprises Group, Inc. It filed for Chapter 11 bankruptcy in November 2023, and that proceeding was converted to Chapter 7 in January 2024.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.